Atlas Trials

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Clinical trial NCT06660862 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06660862
Sponsor
University of Chicago
Status
NOT_YET_RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Prostate Cancer
Start date
2026-11-01
Primary completion
2029-11-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.